Trial Profile
A Study to Compare the Safety and Efficacy of Xience V and Promus Everolimus-Eluting Stents in Patients With Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; Therapeutic Use
- 26 Dec 2015 New trial record